Nordson's Growth Looks Strong

Nordson (NDSN) reported strong Q3 results, primarily driven by its Medical Fluid Solutions and Advanced Technology segments, with growth further boosted by the Atrion acquisition. Despite improved business performance and stable margins, the stock is deemed fairly valued at 24x FCF and 28.5x earnings, presenting no clear undervaluation. Management maintains a cautious FY25 outlook, leading to a reiterated 'Hold' rating, as the analyst sees no compelling reason to buy this high-quality compounder at its current valuation.

Analysis

Nordson Corporation (NDSN) reported strong third-quarter results, with growth primarily driven by its Medical Fluid Solutions and Advanced Technology segments. However, this performance was significantly augmented by the recent acquisition of Atrion, suggesting underlying organic growth may be more modest. Despite a prior 40% decline from its all-time high, the stock is considered fairly valued, trading at a multiple of 24 times free cash flow and 28.5 times earnings, which presents no clear bargain for new investment. Management's outlook for fiscal year 2025 remains cautious, with guidance left unchanged, which contrasts with a slightly more optimistic view from analysts regarding mid-term EPS growth. The prevailing view is that while Nordson is a high-quality compounder with stable margins, its current valuation lacks a compelling thesis for initiating a new position, supporting the 'Hold' rating.

Key Decisions for Investors

• Given the stock is considered fairly valued at 24x FCF and 28.5x earnings, investors should remain on the sidelines and await a more attractive valuation or a positive revision to management's cautious FY25 guidance.
• Current shareholders in NDSN could consider holding their positions, acknowledging the company's high-quality fundamentals, but should moderate expectations for near-term appreciation due to the lack of a clear catalyst.
• Monitor the company's ability to deliver organic growth independent of the Atrion acquisition, as this will be a critical factor in justifying its premium valuation in future reporting periods.